Home > Boards > US Listed > Biotechs > Galera Therapeutics, Inc. (GRTX)

Answer to your remark:

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
PlentyParanoid Member Profile
Member Level 
Followed By 17
Posts 948
Boards Moderated 0
Alias Born 04/26/10
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 1/6/2021 7:06:47 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 12/10/2020 6:04:06 AM
Galera Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference GlobeNewswire Inc. - 11/20/2020 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/17/2020 4:07:24 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/10/2020 7:32:03 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/10/2020 7:08:45 AM
Galera Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Updates GlobeNewswire Inc. - 11/10/2020 7:00:00 AM
Galera Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference GlobeNewswire Inc. - 11/3/2020 8:00:00 AM
Galera Therapeutics Announces Interim Data from Pilot Phase 1/2 Trial of GC4419 in Combination with Stereotactic Body Radiati... GlobeNewswire Inc. - 10/27/2020 3:00:10 PM
Galera Therapeutics Announces Positive Interim Data from First Cohort of Patients in Pilot Phase 1/2 Clinical Trial of GC4419... GlobeNewswire Inc. - 10/23/2020 5:00:10 PM
Galera Therapeutics Announces Dosing of First Patient in the Phase 1/2 GRECO-1 Clinical Trial of GC4711 in Combination with S... GlobeNewswire Inc. - 10/22/2020 8:00:10 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/7/2020 5:02:22 PM
Galera Therapeutics to Host Virtual KOL Event on the Treatment of Locally Advanced Pancreatic Cancer GlobeNewswire Inc. - 9/22/2020 8:00:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/16/2020 8:08:34 AM
Galera Therapeutics Announces Dosing of First Patient in a Randomized, Double-Blind Pilot Phase 2 Clinical Trial of GC4419 fo... GlobeNewswire Inc. - 9/16/2020 8:00:10 AM
Galera Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit GlobeNewswire Inc. - 9/14/2020 8:00:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/9/2020 7:02:34 AM
Galera Therapeutics Announces ASTRO Late-Breaker Presentation of Topline Safety and Efficacy Data from its Double-Blind, Plac... GlobeNewswire Inc. - 9/8/2020 8:00:10 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/10/2020 7:32:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/10/2020 7:11:51 AM
Galera Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates GlobeNewswire Inc. - 8/10/2020 7:00:10 AM
Galera Therapeutics to Participate in Fireside Chat at 2020 BTIG Virtual Biotechnology Conference GlobeNewswire Inc. - 7/30/2020 8:00:10 AM
Galera Therapeutics Completes Enrollment of Phase 1b/2a Clinical Trial of GC4419 in Combination with Radiotherapy for Locally... GlobeNewswire Inc. - 7/13/2020 5:46:38 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/22/2020 4:53:07 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2020 5:48:08 PM
PlentyParanoid Member Level  Monday, 09/07/20 11:01:32 PM
Re: loanranger post# 24
Post # of 27 
Answer to your remark:

"You know that stuff is over my head". I beg to differ, it is not. Staying with Galera for a while. I did some experimenting with those swim-lane values. It seems that even that difference between treatment and placebo should be enough for success in phase 3. My biggest worry is this: what ever I try, I am unable to reconcile placebo swim-lanes with other Galera data for placebo. Maybe they censored some subjects - I don't like that. Well, we should see in October-November time frame.

As to any future IPIX P3 trial. Nobody knows. I am afraid when one possibly comes along, Leo The Clinical Skin-Flint somehow manages to run too small trial, again. I am fairly certain that if either SOM or UPS trial had been done with properly sized population, not with moonshot population, we would now be discussing when we think IPIX P3 results are coming out.

Of course, some will point to thin funds when those trials were done.

"I would rather have questions that can't be answered than answers that can't be questioned." Richard P. Feynman
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences